Related Experiment Video
Updated: Jun 21, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Natural Products for Preventing and Managing Anthracycline-Induced Cardiotoxicity: A Comprehensive Review
Jarosław Szponar1, Przemysław Niziński2, Jarosław Dudka3
1Clinical Department of Toxicology and Cardiology, Toxicology Clinic, Stefan Wyszyński Regional Specialist Hospital, Medical University of Lublin, 20-718 Lublin, Poland.
Abstract:
Doxorubicin (DOX) is an anthracycline anticancer agent that is highly effective in the treatment of solid tumors. Given the multiplicity of mechanisms involved in doxorubicin-induced cardiotoxicity, it is difficult to identify a precise molecular target for toxicity. The findings of a literature review suggest that natural products may offer cardioprotective benefits against doxorubicin-induced cardiotoxicity, both in vitro and in vivo. However, further confirmatory studies are required to substantiate this claim. It is of the utmost importance to direct greater attention towards the intricate signaling networks that are of paramount importance for the survival and dysfunction of cardiomyocytes. Notwithstanding encouraging progress made in preclinical studies of natural products for the prevention of DOX-induced cardiotoxicity, these have not yet been translated for clinical use. One of the most significant obstacles hindering the development of cardioprotective adjuvants based on natural products is the lack of adequate bioavailability in humans. This review presents an overview of current knowledge on doxorubicin DOX-induced cardiotoxicity, with a focus on the potential benefits of natural compounds and herbal preparations in preventing this adverse effect. As literature search engines, the browsers in the Scopus, PubMed, Web of Science databases and the ClinicalTrials.gov register were used.
Insights
Natural products show promise for preventing doxorubicin-induced cardiotoxicity. Further research is needed to confirm benefits and improve bioavailability for clinical use.
Area of Science:
- Cardiology
- Pharmacology
- Oncology
Background:
- Doxorubicin (DOX) is a vital chemotherapy drug for solid tumors.
- DOX-induced cardiotoxicity is a significant clinical challenge with complex mechanisms.
- Identifying effective cardioprotective strategies against DOX is crucial.
Purpose of the Study:
- To review current knowledge on DOX-induced cardiotoxicity.
- To explore the potential cardioprotective effects of natural compounds and herbal preparations.
- To highlight challenges and future directions for developing cardioprotective adjuvants.
Main Methods:
- Comprehensive literature review using Scopus, PubMed, and Web of Science databases.
- Inclusion of data from ClinicalTrials.gov register.
- Focus on in vitro and in vivo studies investigating natural products against DOX cardiotoxicity.
Main Results:
- Evidence suggests natural products may offer cardioprotection against DOX toxicity.
- Preclinical studies show encouraging results for natural product-based interventions.
- Significant obstacles remain, particularly concerning human bioavailability.
Conclusions:
- Natural products represent a promising avenue for mitigating DOX-induced cardiotoxicity.
- Further confirmatory studies are essential to validate these findings.
- Addressing bioavailability issues is critical for clinical translation of these cardioprotective agents.
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cancer Prevention
Some...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

